Enanta reports Q3 net loss $22.7M, cash $272.6M; RSV trials on track

ENANTA PHARMACEUTICALS INC

2024-Q3 EPS reported -$4.12 revenue$53,028,000

Revenue $18.0M (royalty from AbbVie's MAVYRET); net loss $22.7M ($1.07 EPS) vs $39.1M loss a year ago.
Cash, equivalents and securities $272.6M at June 30, 2024; expects runway through Q3 FY2027.
Completed enrollment in RSVPEDs Phase 2 study of zelicapavir in pediatric RSV; topline data expected Q4 2024.
EDP-323 Phase 2a challenge study completed; topline data expected late Q3 2024.
Legal expenses increased due to patent infringement lawsuit against Pfizer; no Q3 earnings call.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.